Skip to main content

Advertisement

SpringerLink
Log in

Single high dose versus repeated bone-targeted radionuclide therapy

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Denis-Bacelar AM, Chittenden S, Dearnaley DP, Divoli A, O’Sullivan JM, McCready VR, et al. Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival. Eur J Nucl Med Mol Imaging. 2017;44(4):620–9.

    Article  CAS  PubMed  Google Scholar 

  2. O’Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;5(86):1715–20.

    Article  Google Scholar 

  3. O’Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B, et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging. 2006;33(9):1055–61.

    Article  PubMed  Google Scholar 

  4. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain. 2002;6(5):323–30.

    Article  PubMed  Google Scholar 

  5. Parker C, Finkelstein SE, Michalski JM, O’Sullivan JM, Bruland Ø, Vogelzang NJ, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline Opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70(5):878–83.

    Article  Google Scholar 

  6. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF, Guhlke S, et al. Palliation and survival after repeated (188)re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52(11):1721–6.

    Article  CAS  PubMed  Google Scholar 

  7. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41.

    Article  CAS  PubMed  Google Scholar 

  8. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, GH Hospital Frankfurt (Oder), Müllroser Chaussee 7, 15236, Frankfurt (Oder), Germany

    K. Liepe

Authors
  1. K. Liepe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Liepe.

Ethics declarations

There are no conflicts of interest.

Human and animal rights and informed consent

No humans or animals were involved.

No informed consent was necessary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liepe, K. Single high dose versus repeated bone-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 44, 2144–2145 (2017). https://doi.org/10.1007/s00259-017-3815-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3815-0

Search

Navigation